Sex | Age Group | Months on ART | ARV analyte exposure | Viral load | Drug resistance mutation by drug class | ||||
---|---|---|---|---|---|---|---|---|---|
EFV | NVP | LPV | NRTI | NNRTI | PI | ||||
Male | 18–29 | 47 | – | – | – | 7327 | Wild-Type | Wild-Type | V82L |
Female | 30–39 | 25 | + | + | – | 8580 | M184V | Y188L | Wild-Type |
Male | 30–39 | N/A | – | – | – | 18,800 | Wild-Type | Wild-Type | I50V |
Female | 30–39 | 21 | + | – | – | 27,474 | K65R, Y115F | V106M, Y181C | Wild-Type |
Male | 40–49 | 92 | – | – | – | 35,300 | M184V | K103N, Y188L | Wild-Type |
Female | 40–49 | 117 | + | – | – | 36,873 | M41L, M184V, T215F | K101E, V106M, G190A | Wild-Type |
Male | 30–39 | N/A | – | – | – | 49,500 | M184I | Wild-Type | M46I |
Female | 30–39 | 90 | + | – | – | 53,600 | K65R, M184V | K101P, K103S | Wild-Type |
Female | 30–39 | 55 | + | – | – | 56,600 | M184V | K103N | Wild-Type |
Male | 30–39 | 49 | + | – | – | 73,200 | D67G, T69D, K70R, M184V, K219Q | L100I, K103N | Wild-Type |
Female | 30–39 | N/A | – | – | – | 95,059 | Wild-Type | K103N | Wild-Type |
Female | 30–39 | 47 | + | – | – | 95,100 | K65R, M184V | Y181C, G190S | Wild-Type |
Female | 30–39 | 61 | + | – | – | 120,000 | K65R, T69del | K101E, Y181C, G190S | Wild-Type |
Male | 18–29 | N/A | – | – | – | 122,000 | Wild-Type | K101E | Wild-Type |
Male | 30–39 | 22 | – | – | – | 135,000 | Wild-Type | K103N | Wild-Type |
Female | 30–39 | 17 | – | – | – | 145,000 | Wild-Type | V106M | Wild-Type |
Male | 40–49 | N/A | – | – | – | 390,000 | Wild-Type | K103N | Wild-Type |
Male | 18–29 | N/A | + | – | – | 415,000 | K65R, Y115F, M184V | V106M, G190A | Wild-Type |
Male | 18–29 | 15 | – | – | – | 490,000 | Wild-Type | K103N, G190A | Wild-Type |
Male | 30–39 | 67 | + | – | – | 799,000 | M41L, D67N, K70E, Y115F, M184V | K103N, V106M | Wild-Type |